Skip to main content
PRTA
NASDAQ Life Sciences

Prothena Reports Strong Q1 Earnings, $50M Milestone, and Significantly Improved 2026 Financial Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.53
Mkt Cap
$566.323M
52W Low
$4.32
52W High
$11.69
52W Position info
144% above low
Off High info
9.9% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

PRTA has more than doubled off its 52-week low of $4.32.

Summary

Prothena announced a substantial financial turnaround in Q1 2026, reporting net income and significantly improving its full-year cash burn and net loss guidance, driven by a $50 million milestone payment.


Key Events · Earnings and Guidance · PRTA

  • Strong Q1 Financial Performance

    Prothena reported net income of $32.7 million ($0.61 diluted EPS) for Q1 2026, a significant reversal from a $60.2 million net loss in Q1 2025, with total revenue increasing to $51.1 million from $2.8 million.

  • $50 Million Milestone Payment Received

    The company received a $50 million clinical milestone payment from Novo Nordisk related to the Phase 3 enrollment of coramitug, which was a primary driver for the improved Q1 financials.

  • Significantly Improved 2026 Financial Guidance

    Prothena updated its full-year 2026 guidance, projecting net cash used in operating and investing activities to be $18 to $23 million (down from $50 to $55 million) and expecting to end the year with approximately $273 million in cash, an increase of $18 million from prior guidance.

  • Pipeline Advancement and Potential Future Milestone

    Positive clinical updates were provided for prasinezumab (Parkinson's disease), and the Phase 1 study for PRX019 was completed, with a potential $55 million clinical milestone payment from Bristol Myers Squibb expected by year-end 2026 if the program advances.


Analysis · PRTA · Life Sciences

This 8-K, furnishing the Q1 2026 earnings press release, signals a major positive shift for Prothena. The company achieved a significant financial turnaround, moving from a substantial loss to net income, primarily fueled by a $50 million milestone payment from Novo Nordisk. Crucially, Prothena also provided significantly improved financial guidance for 2026, projecting a much lower cash burn and a higher year-end cash balance. These developments, coupled with positive clinical updates across its partnered pipeline, demonstrate strong operational execution and enhance the company's financial stability and long-term prospects. Investors should note the potential for an additional $55 million milestone payment later this year.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRTA was trading at $10.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $566.3M. The 52-week trading range was $4.32 to $11.69. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRTA - Latest Insights

PRTA
Nov 05, 2026, 5:55 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.17 info
Change: +$0.280 (+4%) info
Market Cap: $419.014M info
PRTA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.17 info
Change: +$0.280 (+4%) info
Market Cap: $419.014M info
PRTA
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.88
Real-time Price: $8.17 info
Change: -$0.710 (-8%) info
Market Cap: $419.014M info
PRTA
Aug 06, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.17 info
Change: -$0.410 (-5%) info
Market Cap: $419.014M info
PRTA
Aug 06, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.17 info
Change: -$0.410 (-5%) info
Market Cap: $419.014M info